Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
65.35
+0.24 (+0.37%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
February 25, 2025
From
Exelixis, Inc.
Via
Business Wire
This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
↗
February 24, 2025
Via
Benzinga
Why Exelixis Stock Trounced the Market on Thursday
↗
February 21, 2025
Via
The Motley Fool
Why Is Cancer-Focused Exelixis Stock Trading Higher On Friday?
↗
February 21, 2025
Exelixis reaffirmed its 2025 sales guidance of $2.15-$2.25 billion and reported sustained long-term efficacy for Cabometyx in advanced renal cell carcinoma.
Via
Benzinga
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
February 20, 2025
From
Exelixis, Inc.
Via
Business Wire
A Glimpse Into The Expert Outlook On Exelixis Through 21 Analysts
↗
February 12, 2025
Via
Benzinga
2 Stocks to Buy With Less Than $40
↗
February 10, 2025
Via
The Motley Fool
Don't overlook NASDAQ:EXEL—a stock with solid growth prospects and a reasonable valuation.
↗
February 19, 2025
NASDAQ:EXEL is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Via
Chartmill
Top 5 Biotech Stocks That Got Most Retail Buzz Last Week
↗
February 17, 2025
From merger updates to earnings surprises, these healthcare stocks saw the biggest spike in Stocktwits chatter.
Via
Stocktwits
Bullish Setups
↗
February 16, 2025
You know things are bad when I stoop to offering some bullish setups, but that’s just where we’re at right now.
Via
Talk Markets
Topics
Stocks / Equities
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
February 15, 2025
From
Exelixis, Inc.
Via
Business Wire
15 Analysts Have This To Say About Exelixis
↗
January 15, 2025
Via
Benzinga
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
February 13, 2025
From
Exelixis, Inc.
Via
Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
February 12, 2025
Via
Benzinga
Exelixis (EXEL) Q4 2024 Earnings Call Transcript
↗
February 11, 2025
EXEL earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exelixis Posts 63.7% Profit Surge
↗
February 11, 2025
Exelixis reported increased revenue and earnings in Q4 2024, driven by strong cabozantinib sales, though competitive pressures and regulatory challenges remain.
Via
The Motley Fool
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
February 11, 2025
From
Exelixis, Inc.
Via
Business Wire
Earnings Scheduled For February 11, 2025
↗
February 11, 2025
Via
Benzinga
NASDAQ:EXEL: good value for what you're paying.
↗
February 04, 2025
EXELIXIS INC is a hidden gem, featuring undervaluation and robust fundamentals. NASDAQ:EXEL showcases decent financial health and profitability, coupled with an attractive price.
Via
Chartmill
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
January 28, 2025
From
Exelixis, Inc.
Via
Business Wire
Investors should take note of NASDAQ:EXEL, a growth stock that remains attractively priced.
↗
January 27, 2025
Uncover the potential of EXELIXIS INC, a growth stock reasonably priced. NASDAQ:EXEL is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation.
Via
Chartmill
Abbott To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Monday
↗
January 27, 2025
Via
Benzinga
This Twilio Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
↗
January 27, 2025
Via
Benzinga
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
January 25, 2025
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
January 24, 2025
From
Exelixis, Inc.
Via
Business Wire
BeiGene Stock Meets 80-Plus RS Rating Benchmark
↗
January 15, 2025
One key metric to look for in a stock is an 80-plus Relative Strength Rating. BeiGene stock just hit that mark, with a jump to 84 Wednesday.
Via
Investor's Business Daily
BridgeBio Pharma Stock Earns 87 RS Rating
↗
January 14, 2025
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87.
Via
Investor's Business Daily
NASDAQ:EXEL appears to be flying under the radar despite its strong fundamentals.
↗
January 14, 2025
EXELIXIS INC (NASDAQ:EXEL) is probably undervalued for the fundamentals it is displaying.
Via
Chartmill
SpringWorks Therapeutics Stock Sees RS Rating Jump To 86
↗
January 13, 2025
On Monday, SpringWorks Therapeutics stock hit a key technical milestone, seeing its Relative Strength Rating jump to 86.
Via
Investor's Business Daily
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
January 12, 2025
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
23
24
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
